The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated
